技术指标
指标
数值
方向
MACD(12,26,9)
-0.513
卖出
RSI(14)
35.593
中性
STOCH(KDJ)(9,3,3)
12.261
超卖
ATR(14)
0.840
高波动
CCI(14)
-119.113
卖出
Williams %R
95.906
超卖
TRIX(12,20)
-0.363
卖出
StochRSI(14)
37.090
卖出
搜索
Zymeworks Inc
ZYME添加自选
21.940USD
-0.770-3.39%
收盘 07-31 16:00（美东）报价延迟15分钟
1.57B总市值
亏损市盈率 TTM
关键数据
22.745今开
22.745最高
375.12K成交量
亏损市盈率 TTM
26.36市盈率动
--股息TTM
0.50%换手率
22.710昨收
21.800最低
5.77M成交额
亏损市盈率静
6.14市净率
0.00%股息率 TTM
-22.72%ROA
29.75052周最高
1.08量比
-122.69M净利润
75.19M总股本
-1.3662每股收益TTM
1.16Beta
-42.02%ROE
11.02052周最低
4.16%振幅
100.00%毛利率
1.57B总市值
-4.07回报/风险
2.54%风险率
TradingKey Zymeworks Inc股票评分
单位: USD 更新时间: 2026-07-31操作建议
Zymeworks Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名44/385位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价39.33。中期看，股价处于下降通道。近一个月，市场表现较差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Zymeworks Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Zymeworks Inc亮点
亮点风险
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
分析师目标
根据
12
位分析师
买入
评级
39.333
目标均价
+79.28%
涨幅空间
Zymeworks Inc新闻
即将为您带来更多新闻，敬请期待。。。
收益预测
分析师评级
根据
12
位分析师
买入
评级
39.333
目标均价
+79.28%
涨幅空间
强力买入
买入
持有
卖出
强力卖出
同行比较
496
总数
6
中位数
7
平均值
公司名称
评级分布
分析师数
Zymeworks Inc
ZYME
12
百济神州
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
艾昆纬
IQV
26
Kymera Therapeutics Inc
KYMR
24
1
2
3
...
99
技术指标
移动平均线
指标
数值
方向
MA5
22.454
卖出
MA10
22.942
卖出
MA20
24.185
卖出
MA50
24.235
卖出
MA100
24.960
卖出
MA200
23.983
卖出
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Zymeworks Inc简介
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
公司代码ZYME
公司Zymeworks Inc
CEOGalbraith (Kenneth H)
网址https://www.zymeworks.com/
公司股东
相关品种
热门品种
常见问题
Zymeworks Inc(ZYME)的当前股价是多少？
Zymeworks Inc(ZYME)的当前股价是 21.94。
Zymeworks Inc的股票代码是什么？
Zymeworks Inc的股票代码是ZYME。
Zymeworks Inc股票的52周最高点是多少？
Zymeworks Inc股票的52周最高点是29.75。
Zymeworks Inc股票的52周最低点是多少？
Zymeworks Inc股票的52周最低点是11.02。
Zymeworks Inc的市值是多少？
Zymeworks Inc的市值是1.57B。
现在Zymeworks Inc(ZYME)的股票是买入、持有还是卖出？
根据分析师评级，Zymeworks Inc(ZYME)的总体评级为买入，目标价格为39.33。
Zymeworks Inc(ZYME)股票的每股收益（EPS TTM）是多少
Zymeworks Inc(ZYME)股票的每股收益（EPS TTM）是-1.08。